Axonics (AXNX)
(Delayed Data from NSDQ)
$69.60 USD
+0.34 (0.49%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $69.63 +0.03 (0.04%) 4:32 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
AXNX 69.60 +0.34(0.49%)
Will AXNX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AXNX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AXNX
Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic
Axonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates
AXNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
Other News for AXNX
Deals this week: Smartsheet, AT&T, BP, Cleveland-Cliffs, Vistra and more
Axonics Prevails in Patent Infringement Lawsuit with Medtronic
Axonics prevails in patent infringement lawsuit with Medtronic
Axonics gains after win in trial in patent dispute with Medtronic
Tracking George Soros's 13F Portfolio - Q2 2024 Update